HOME - OUR SCIENCE - Pipeline - ES028

ES028 is a potential first-in-class SIRPα/CLDN18.2 bsAb developed using our BiME platform. ES028 potentially bridges activated macrophages to solid tumors for direct phagocytosis. Although ES028 is still at a relatively early stage of development, the molecule has demonstrated the tremendous potential of the BiME platform for solid tumors. ES028 is currently in the candidate selection stage. We expect to develop ES028 as a monotherapy to provide an “eat-me” signal that can induce full activation of macrophage phagocytosis. Additionally, ES028 has the potential to be combined with chemotherapy in earlier lines of therapy. We plan to file an IND application with the FDA in the second half of 2023.